Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Biosens Bioelectron ; 16(9-12): 971-7, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11679277

RESUMEN

Recombinant bovine somatotropin (rBST) treatment is adopted in dairy cows to augment milk yield. Previous studies showed that insulin-like growth factor-1 (IGF-1) is present in milk from cows treated with rBST. Since IGF-1 is a suspected carcinogen, its presence in milk for human consumption is potentially a health hazard. Therefore rBST use, still authorized in the United States, has been revoked in Canada and is under evaluation in the EU. The rising attention on IGF-1 presence in alimentary milk focused the necessity to develop specific, sensitive and rapid IGF-1 detection systems. We have developed a solid phase enzyme-linked immunoassay (ELISA) and also an automated surface plasmon resonance-based biosensor system (BIA-technology) for evaluating IGF-1 in fresh cow's milk. Hyperimmune polyclonal anti-IGF-1 antibodies were characterized with respect to their specific binding capacity to IGF-1. The results obtained with these two methods have been compared. This study shows the potential usefulness of the biosensor technology for biomolecular interaction analysis. The features of this technology (fully automated, measures in real time, sharpened yes/no response) offer several advantages compared to ELISA in the detection of compounds in fresh cows' milk (MURST 40%; CNR P.F. MADESS 2).


Asunto(s)
Ensayo de Inmunoadsorción Enzimática/métodos , Factor I del Crecimiento Similar a la Insulina/análisis , Leche/química , Resonancia por Plasmón de Superficie/métodos , Animales , Bovinos , Contaminación de Alimentos/análisis , Hormona del Crecimiento/farmacología , Humanos , Factor I del Crecimiento Similar a la Insulina/efectos adversos , Proteínas Recombinantes/farmacología
3.
J Chemother ; 4(3): 171-5, 1992 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1517811

RESUMEN

This study analyzed the cost-effectiveness of antibiotic treatments of different durations for acute cystitis in non-pregnant females. Questionnaires were sent to 400 practitioners evenly distributed throughout Italy. Data are reported from 2,069 patients. The clinical bacteriological efficacy at 10-15 days was 86.4% for single-dose treatment with fosfomycin-trometamol (FT), and 81.8% for the multiple-dose antibiotics group (MDAG). Disappearance of symptoms occurred in 2.1 days with FT and 3.4 days with MDAG. With FT 93.8% of patients were free of adverse events and 86.9% with MDAG. Analysis of the cost-effectiveness indicators for cure rate and absence of adverse events showed that treatment costs were similar for all antibiotics. FT needed less time interval for symptoms to disappear with a slightly higher cost than for MDAG, which had a better cost/effectiveness ratio.


Asunto(s)
Antibacterianos/economía , Quimioterapia Combinada/economía , Infecciones Urinarias/tratamiento farmacológico , Adulto , Antibacterianos/administración & dosificación , Cefalosporinas/administración & dosificación , Cefalosporinas/economía , Análisis Costo-Beneficio , Esquema de Medicación , Quimioterapia Combinada/administración & dosificación , Femenino , Fosfomicina/administración & dosificación , Fosfomicina/economía , Humanos , Piperacilina/administración & dosificación , Piperacilina/economía , Factores de Tiempo , Trometamina/administración & dosificación , Trometamina/economía
4.
Infection ; 20 Suppl 4: S291-5, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1294520

RESUMEN

In order to assess the resistance profile for fosfomycin trometamol after several years of clinical use in Italy, this study has explored the susceptibility to fosfomycin and eight other antibacterial drugs of 6,021 strains isolated from 23,816 urines during 1990 in three teaching hospitals located in Genoa, Parma and Catania. Gram-negative strains, notably Escherichia coli (41.6%), were primarily involved. Amoxicillin was the least active compound with resistance in 41.4% of the isolates. Fosfomycin showed the lowest rate of resistance in both gram-negative (2.8%) and gram-positive (2.1%) pathogens. This was followed by norfloxacin with a resistance rate of 11.8% and netilmicin with 12.2%. These results indicate that fosfomycin-trometamol may continue to be used in single-dose treatment of urinary tract infections even in the absence of microbiological data since the prevalence of resistance to the drug is, at present, so low that therapeutic failure is highly improbable.


Asunto(s)
Antibacterianos/farmacología , Enterobacteriaceae/efectos de los fármacos , Fosfomicina/farmacología , Cocos Grampositivos/efectos de los fármacos , Infecciones Urinarias/microbiología , Antiinfecciosos Urinarios/farmacología , Farmacorresistencia Microbiana , Humanos , Italia , Pruebas de Sensibilidad Microbiana
6.
Ophthalmologica ; 192(2): 82-7, 1986.
Artículo en Inglés | MEDLINE | ID: mdl-3703483

RESUMEN

Two families are described with members affected by Brown's syndrome. Another case of Brown's syndrome is described in a dizygotic twin. The authors suggest a hypothesis for the influence of heredity in Brown's syndrome.


Asunto(s)
Trastornos del Movimiento/genética , Músculos Oculomotores , Niño , Preescolar , Movimientos Oculares , Femenino , Humanos , Masculino , Trastornos del Movimiento/fisiopatología , Linaje , Síndrome
7.
Arch Fr Pediatr ; 37(4): 259-61, 1980 Apr.
Artículo en Francés | MEDLINE | ID: mdl-7406642

RESUMEN

The case of a 2 year old girl with myasthenia gravis is reported. Immunological investigations did not show any major abnormalities of the thymocytes. High levels of acetylcholine receptor antibodies were present before thymectomy. After surgery they decreased significantly and there was a clear clinical improvement.


Asunto(s)
Miastenia Gravis/terapia , Timectomía , Preescolar , Femenino , Humanos , Miastenia Gravis/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA